Author:
Goldschmidt Jerome,Hanes Vladimir
Publisher
Springer Science and Business Media LLC
Reference32 articles.
1. MVASI™ (bevacizumab-awwb) for injection, for intravenous use. Prescribing information. Amgen Inc., Thousand Oaks, CA: 2020. https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/mvasi/mvasi_pi_hcp_english.pdf. Accessed August 27, 2020.
2. MVASI. Summary of product characteristics. Amgen Europe B.V., the Netherlands: 18 December 2020. https://www.ema.europa.eu/en/medicines/human/EPAR/mvasi#productinformation-section. Accessed August 27, 2020.
3. Thomas M, Thatcher N, Goldschmidt J, Ohe Y, McBride HJ, Hanes V. Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar. Immunotherapy. 2019;11(5):1337–51.
4. Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176:1248–64.
5. Markus R, Liu J, Ramchandani M, Landa D, Born T, Kaur P. Developing the totality of evidence for biosimilars: regulatory considerations and building confidence for the healthcare community. BioDrugs. 2017;31(3):175–87.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献